Dr Nicola Bougen-Zhukov
| Position | Research Fellow |
|---|---|
| Department | Department of Biochemistry |
| Qualifications | PhD |
| Research summary | Cancer genetics |
Research
In September 2017 I joined the Cancer Genetics Laboratory, headed by Professor Parry Guilford. Here, I am on the team working towards new treatment strategies for hereditary and sporadic gastric cancers, specifically those cancers lacking E-cadherin expression. Our goal is to identify drugs which have a synthetic lethal relationship with E-cadherin mutations/silencing and specifically target cancer cells.
We use a variety of models to screen for new drugs, such as cells lines, organoids (mouse and human derived), and our own mouse models.? I am particularly interested in drug mediated modulation of AKT signalling E-cadherin negative cells.
Publications
Bougen-Zhukov, N., Decourtye-Espiard, L., Mitchell, W., Redpath, K., Perkinson, J., Godwin, T., Black, M. A., & Guilford, P. (2022). E-cadherin-deficient cells are sensitive to the multikinase inhibitor dasatinib. Cancers, 14, 1609. doi: 10.3390/cancers14071609
Gullo, I., Oliveira, C., van der Post, R. S., van Dieren, J. M., Davis, J. L., Bougen-Zhukov, N., Guilford, P., & Carneiro, F. (2021). Updated perspective and directions on hereditary diffuse gastric cancer. In B. Jenkins (Ed.), Research and clinical applications of targeting gastric neoplasms. (pp. 217-258). London, UK: Elsevier. doi: 10.1016/B978-0-323-85563-1.00011-3
Brew, T., Bougen-Zhukov, N., Mitchell, W., Decourtye, L., Schulpen, E., Nouri, Y., Godwin, T., & Guilford, P. (2021). Loss of E-cadherin leads to druggable vulnerabilities in sphingolipid metabolism and vesicle trafficking. Cancers, 14(1), 102. doi: 10.3390/ cancers14010102
Decourtye-Espiard, L., Bougen-Zhukov, N., Godwin, T., Brew, T., Schulpen, E., Black, M. A., & Guilford, P. (2021). E-cadherin-deficient epithelial cells are sensitive to HDAC inhibitors. Cancers, 14(1), 175. doi: 10.3390/ cancers14010102
Luxenburger, A., Bougen-Zhukov, N., Fraser, M. G., Beetham, H., Harris, L. D., Schmidt, D., … Guilford, P. J., & Evans, G. B. (2021). Discovery of AL-GDa62 as a potential synthetic lethal lead for the treatment of gastric cancer. Journal of Medicinal Chemistry, 64, 18114-18142. doi: 10.1021/acs.jmedchem.1c01609
Gullo, I., Oliveira, C., van der Post, R. S., van Dieren, J. M., Davis, J. L., Bougen-Zhukov, N., Guilford, P., & Carneiro, F. (2021). Updated perspective and directions on hereditary diffuse gastric cancer. In B. Jenkins (Ed.), Research and clinical applications of targeting gastric neoplasms. (pp. 217-258). London, UK: Elsevier. doi: 10.1016/B978-0-323-85563-1.00011-3
Chapter in Book - Research
Bougen-Zhukov, N., Decourtye-Espiard, L., Mitchell, W., Redpath, K., Perkinson, J., Godwin, T., Black, M. A., & Guilford, P. (2022). E-cadherin-deficient cells are sensitive to the multikinase inhibitor dasatinib. Cancers, 14, 1609. doi: 10.3390/cancers14071609
Journal - Research Article
Brew, T., Bougen-Zhukov, N., Mitchell, W., Decourtye, L., Schulpen, E., Nouri, Y., Godwin, T., & Guilford, P. (2021). Loss of E-cadherin leads to druggable vulnerabilities in sphingolipid metabolism and vesicle trafficking. Cancers, 14(1), 102. doi: 10.3390/ cancers14010102
Journal - Research Article
Decourtye-Espiard, L., Bougen-Zhukov, N., Godwin, T., Brew, T., Schulpen, E., Black, M. A., & Guilford, P. (2021). E-cadherin-deficient epithelial cells are sensitive to HDAC inhibitors. Cancers, 14(1), 175. doi: 10.3390/ cancers14010102
Journal - Research Article
Luxenburger, A., Bougen-Zhukov, N., Fraser, M. G., Beetham, H., Harris, L. D., Schmidt, D., … Guilford, P. J., & Evans, G. B. (2021). Discovery of AL-GDa62 as a potential synthetic lethal lead for the treatment of gastric cancer. Journal of Medicinal Chemistry, 64, 18114-18142. doi: 10.1021/acs.jmedchem.1c01609
Journal - Research Article
Bougen-Zhukov, N. M., Lee, Y. Y., Lee, J.-Y. J., Lee, P., & Loo, L.-H. (2020). P13K catalytic subunits α and β modulate cell death and IL-6 secretion induced by talc particles in human lung carcinoma cells. American Journal of Respiratory Cell & Molecular Biology, 62(3), 331-341. doi: 10.1165/rcmb.2019-0050OC
Journal - Research Article
Bougen-Zhukov, N., Nouri, Y., Godwin, T., Taylor, M., Hakkaart, C., Single, A., Brew, T., Permina, E., Chen, A., Black, M. A., & Guilford, P. (2019). Allosteric AKT inhibitors target synthetic lethal vulnerabilities in E-cadherin-deficient cells. Cancers, 11(9), 1359. doi: 10.3390/cancers11091359
Journal - Research Article
Godwin, T. D., Kelly, S. T., Brew, T. P., Bougen-Zhukov, N. M., Single, A. B., Chen, A., Stylianou, C. E., … Currie, S. K., Telford, B. J., Beetham, H. G., … Black, M. A., & Guilford, P. J. (2019). E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. Gastric Cancer, 22(2), 273-286. doi: 10.1007/s10120-018-0859-1
Journal - Research Article
Bougen-Zhukov, N., Loh, S. Y., Lee, H. K., & Loo, L.-H. (2017). Large-scale image-based screening and profiling of cellular phenotypes. Cytometry Part A, 91(2), 115-125. doi: 10.1002/cyto.a.22909
Journal - Research Article
Loo, L.-H., Bougen-Zhukov, N. M., & Tan, W.-L. C. (2017). Early spatiotemporal-specific changes in intermediate signals are predictive of cytotoxic sensitivity to TNFα and co-treatments. Scientific Reports, 7, 43541. doi: 10.1038/srep43541
Journal - Research Article
Bougen, N. M., Amiry, N., Yuan, Y., Kong, X. J., Pandey, V., Vidal, L. J. P., … Lobie, P. E. (2013). Trefoil factor 1 suppression of E-CADHERIN enhances prostate carcinoma cell invasiveness and metastasis. Cancer Letters, 332(1), 19-29. doi: 10.1016/j.canlet.2012.12.012
Journal - Research Article
Banerjee, A., Qian, P., Wu, Z.-S., Ren, X., Steiner, M., Bougen, N. M., … Lobie, P. E. (2012). Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells. Journal of Biological Chemistry, 287(51), 42502-42515. doi: 10.1074/jbc.M112.365163
Journal - Research Article
Bougen, N. M., Steiner, M., Pertziger, M., Banerjee, A., Brunet-Dunand, S. E., Zhu, T., … Perry, J. K. (2012). Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells. Endocrine-Related Cancer, 19(5), 625-644. doi: 10.1530/ERC-12-0042
Journal - Research Article
Bougen, N. M., Yang, T., Chen, H., Lobie, P. E., & Perry, J. K. (2011). Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C. Oncology Reports, 26, 487-493. doi: 10.3892/or.2011.1305
Journal - Research Article
Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., van Dieren, J. M., … Paringatai, K., Bougen-Zhukov, N., Brew, T., … Godwin, T. D., … Nouri, Y., … Reeve, A. E., & Guilford, P. (2020). Hereditary diffuse gastric cancer: Updated clinical practice guidelines. Lancet Oncology, 21(8), e386-e397. doi: 10.1016/S1470-2045(20)30219-9
Journal - Research Other
